However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.
Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback